Subramanian Sankar - 26 Sep 2022 Form 4 Insider Report for Nautilus Biotechnology, Inc. (NAUT)

Role
Senior VP, Product Development
Signature
/s/ Matthew B. Murphy, as Attorney-in-Fact
Issuer symbol
NAUT
Transactions as of
26 Sep 2022
Net transactions value
+$30,399
Form type
4
Filing time
28 Sep 2022, 16:01:57 UTC
Previous filing
19 Sep 2022
Next filing
01 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NAUT Common Stock Purchase $20,250 +10,000 +13% $2.02 86,250 26 Sep 2022 Direct F1, F2
transaction NAUT Common Stock Purchase $10,149 +5,000 +5.8% $2.03 91,250 27 Sep 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the weighted average share price of an aggregate total of 10,000 shares purchased in the price range of $2.00 to $2.05 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F2 Includes 1,250 shares of Common Stock acquired on June 1, 2022 through the Issuer's 2021 Employee Stock Purchase Plan.
F3 Represents the weighted average share price of an aggregate total of 5,000 shares purchased in the price range of $2.02 to $2.04 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.